The antibody TBL‐100 binds with picomolar affinity and high specificity to the free carboxy terminus of tauC3 in tau oligomers involved in spreading of pathology in AD

TBL-100 has exquisite end specificity for tau cleaved at Asp421 (tauC3). It bound oligomeric tauC3 with the same high affinity as it bound monomeric tauC3, supporting TBL-100's potential to interrupt oligomer-driven spreading of pathology. TBL-100's high affinity and specificity for pathogenic tau support its development as a treatment for tauopathies.